A Study to Investigate Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Healthy Volunteers

NCT02596399 | Completed Phase 1

• 1 other identifier: GV29259
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

This is a Phase 1, randomized, double-blind, placebo-controlled, single-ascending dose study in healthy volunteers, enrolled at a single site in the United States to investigate the safety, tolerability, and pharmacokinetics of DSTA4637S.

Conditions

Healthy Volunteer

Keywords

Healthy volunteers; DSTA4637S

Outcome Measures

Primary Outcomes (1)

• Number of Participants with at least 1 Adverse Event (AE)

  Up to Day 85

Secondary Outcomes (2)

• Concentration of analytes of DSTA4637S in plasma and serum

  Up to Day 85

• Concentration of anti-therapeutic antibodies (ATA) to DSTA4637S

  Up to Day 85

Study Arms (2)

DSTA4637S

EXPERIMENTAL

Drug: DSTA4637S

Placebo

PLACEBO COMPARATOR

Drug: Placebo

Interventions

DSTA4637S DRUG

Participants will receive DSTA4637S intravenously on Day 1.

DSTA4637S

Placebo DRUG

Participants will receive placebo matched to DSTA4637S intravenously on Day 1.

Placebo

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Signed Informed Consent Form
• Able to comply with the study protocol, in the investigator's judgment
• Body mass index (BMI) between 18 and 32 kilogram per square meters (kg/m\^2), inclusive
• In good health, determined by no clinically significant findings from medical history, 12-lead electrocardiogram (ECG), and vital signs
• Clinical laboratory evaluations should be within the reference range for the test laboratory unless deemed not clinically significant by the investigator and Sponsor
• Willing to abstain from the use of drugs of abuse through completion of the study
• Willing to abstain from use of over the counter, herbal or prescription medications/products from 14 days prior to Day 1 through completion of the study, unless deemed acceptable by the investigator and Sponsor
• Agreeable to, and deemed able to (by the investigator), comply with requirements of the study, including the follow-up period
• Willing to abstain from consumption of alcohol-based products from 72 hours prior to Day 1 until Phase 1 unit check-out on Day 3 and for 72 hours prior to each follow-up visit
• For women of childbearing potential, agreement to remain abstinent (refrain from heterosexual intercourse) or use non-hormonal contraceptive methods that result in a failure rate of less than (\<) 1 percent (%) per year during the treatment period and for at least 85 days after the last dose of study drug
• For men, agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating sperm, as defined in the study protocol

You may not qualify if:

• Any diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that in the opinion of the investigator or Sponsor contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the subject at high risk from treatment complications
• Use of tobacco, electronic cigarettes, personal vaporizer or electronic nicotine delivery systems (positive history within 3 months before initiation of dosing on Day 1)
• Received any vaccine within 14 days prior to screening
• Pregnant or lactating, or intending to become pregnant within 3 months after screening
• Positive serum pregnancy test result at screening or Day \&#8722;1
• Received oral antibiotics within 4 weeks before initiation of dosing on Day 1, or intravenous antibiotics within 8 weeks before initiation of dosing
• Hospitalization within 4 weeks before initiation of dosing
• Positive for hepatitis C virus (HCV) antibody, hepatitis B surface antigen (HBsAg), or human immunodeficiency virus (HIV) antibody
• History of significant drug abuse within 1 year prior to screening or use of soft drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs (such as cocaine, phencyclidine, and crack) within 1 year prior to screening
• Positive drug screen at screening or Day -1
• History of anaphylactic or hypersensitivity drug reaction, unless approved by the investigator and Sponsor
• Blood transfusion within 8 weeks prior to screening
• History of malignancy within 10 years of screening except completely excised basal cell carcinoma or squamous cell carcinoma of the skin
• Donation of plasma (greater than or equal to \[\>=\] 500 milliliter \[mL\]) within 7 days prior to study drug administration
• Donation or loss of whole blood (excluding the volume of blood that will be drawn during screening procedures) as follows: 50-499 mL of whole blood within 30 days or greater than (\>) 499 mL of whole blood within 56 days prior to study drug administration

Sponsors & Collaborators

• Genentech, Inc.: lead

Study Sites (1)

PRA International Clinical Pharmacology Center (EDS US Clinic)

Lenexa, Kansas, 66219, United States

Location

Related Publications (1)

• Peck M, Rothenberg ME, Deng R, Lewin-Koh N, She G, Kamath AV, Carrasco-Triguero M, Saad O, Castro A, Teufel L, Dickerson DS, Leonardelli M, Tavel JA. A Phase 1, Randomized, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S, an Anti-Staphylococcus aureus Thiomab Antibody-Antibiotic Conjugate, in Healthy Volunteers. Antimicrob Agents Chemother. 2019 May 24;63(6):e02588-18. doi: 10.1128/AAC.02588-18. Print 2019 Jun.

  PMID: 30910894 DERIVED

Study Officials

• Clinical Trials

  Hoffmann-La Roche

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 3, 2015
• First Posted: November 4, 2015
• Study Start: November 29, 2015
• Primary Completion: May 30, 2016
• Study Completion: May 30, 2016
• Last Updated: March 6, 2018

Record last verified: 2018-03

Locations

US (1)